Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Menadione

FDA-approved product (tablet, oral), marketed as Menadione.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Menadione
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vitamin k
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Menadione in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Menadione with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • DULCIS (D-dimer and ULtrasonography in Combination Italian Study)

    NCT00954395 · start 2008-09

    Registered record
    Registry ID
    NCT00954395
    Conditions
    Venous Thromboembolism
    Interventions
    D-dimer
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-09
    Completion
    2012-06
    Enrolment
    1,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionD-dimer
    PhaseNot recorded
    Registry statusCompleted

  • The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients

    NCT01235325 · start 2008-07

    Registered record
    Registry ID
    NCT01235325
    Conditions
    Supplementation; Bone Health; Crohn's Disease
    Interventions
    phylloquinone (vitamin K1); placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-11
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSupplementation; Bone Health; Crohn's Disease
    Interventionphylloquinone (vitamin K1); placebo
    PhasePhase 4
    Registry statusCompleted

  • Predictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death

    NCT01864122 · start 2007-01

    Registered record
    Registry ID
    NCT01864122
    Conditions
    Cardiovascular Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-01
    Completion
    2010-10
    Enrolment
    2,448

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial

    NCT00355290 · start 2006-08

    Registered record
    Registry ID
    NCT00355290
    Conditions
    Blood Coagulation Disorders
    Interventions
    Changes on Oral Vitamin K Intake
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-08
    Completion
    2007-12
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlood Coagulation Disorders
    InterventionChanges on Oral Vitamin K Intake
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification

    NCT00183001 · start 2001-10

    Registered record
    Registry ID
    NCT00183001
    Conditions
    Osteoporosis; Vascular Calcification; Inflammation
    Interventions
    Vitamin K
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10
    Completion
    2006-10
    Enrolment
    452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis; Vascular Calcification; Inflammation
    InterventionVitamin K
    PhasePhase 3
    Registry statusCompleted